Glenmark Life Sciences is launching its IPO. The public offer comprises a fresh issue of equity shares worth Rs. 1,160 crores and offer for sale of 63 lakh equity shares by its parent company Glenmark Pharmaceuticals Ltd.
About the company:
Glenmark Life Sciences is a leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs) catering to chronic therapeutic areas such as cardiovascular disease, central nervous system disorders, pain management, and diabetes, among others. As of December 31, 2020, the company had a portfolio of 120 molecules globally and sold its APIs in India as well as to multiple countries in Europe, North America, Latin America, Japan, and the rest of the world.
|Financial Year Ended||Revenue (₹ Crores)||PAT (₹ Crores)||EPS (₹)|
For more information, you can refer to the IPO Prospectus filed by the company.
|Issue Period||27th July 2021 to 29th July 2021|
|Price Range||₹ 695 to 720|
|Minimum Bid Quantity||20 and in multiples thereof|
|Finalisation of Allotment||3rd August 2021|
|Initiation of Refunds||4th August 2021|
|Credit of Shares||5th August 2021|
|Listing Date||6th August 2021|
How do I apply to the Glenmark Life Sciences IPO?
You can apply for the Glenmark Life Sciences IPO using any supported UPI app by following two steps:
Enter your bid on Console
Accept UPI mandate on your phone
On acceptance of the mandate, the bid amount will get blocked in your bank account. Click here to learn more.